BRAF mutations and concurrent alterations in patients with soft tissue sarcoma

BRAF alterations, including V600E and non‐V600E mutations and fusions, in soft tissue sarcoma (STS) have been identified in a limited case series. Here, we aimed to evaluate the frequency of BRAF mutations and concurrent alterations in STS to understand their therapeutic action. In this retrospective analysis, we included data from 1964 patients with advanced STS who underwent comprehensive genomic profiling tests at hospitals in Japan between June 2019 and March 2023. The prevalence of BRAF and recurrent concurrent gene alterations were also investigated. BRAF mutations were detected in 24 (1.2%) of 1964 STS patients, with a median age of 47 (range 1–69) years. BRAF V600E was detected in 11 (0.6%) of the 1964 patients with STS, BRAF non‐V600E mutations in 9 (4.6%), and BRAF fusions were detected in 4 (0.2%). BRAF V600E was identified in 4 (0.2%) cases of malignant peripheral nerve sheath tumors. The most common concurrent alteration was CDKN2A (11 cases, 45.8%), and the frequency was equivalent to that of the BRAF V600E (5/11 cases, 45.5%) and non‐V600E (5/9 cases, 55.6%) groups. Recurrent concurrent alterations, such as TERT promoter mutations (7 cases, 29.2%), were detected at the same frequency in the V600E and non‐V600E groups. In contrast, TP53 alterations (4/9 cases, 44.4%) and mitogen‐activated protein kinase (MAPK)‐activating genes, including NF1, GNAQ, and GNA11 (3/9 cases, 33.3%), were identified as relatively higher in the non‐V600E group than in the V600E group (each 1/11 case, 9.1%). We identified BRAF alterations at a rate of 1.2% in all patients with advanced STS. Among them, BRAF V600E and BRAF fusions account for 45.8% and 16.7%, respectively. Collectively, our findings support the clinical characteristics and therapeutic strategies for patients with BRAF‐altered advanced STS.

[1]  Xue Wu,et al.  The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses , 2023, Biomarker Research.

[2]  C. Serrano,et al.  Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database , 2023, Frontiers in Oncology.

[3]  H. Aburatani,et al.  Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan , 2023, Cancer science.

[4]  J. García-Donas,et al.  MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer , 2022, Clinical and Translational Oncology.

[5]  Yi Du,et al.  Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review , 2022, Frontiers in Oncology.

[6]  Narasimhan P. Agaram,et al.  Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma , 2022, Nature Communications.

[7]  S. Grimmond,et al.  Primary pancreatic spindle cell sarcoma with a TMEM106B::BRAF gene fusion treated with MEK inhibition. , 2022, Pathology.

[8]  Jessica L. Davis,et al.  Histologic characterization of paediatric mesenchymal neoplasms treated with kinase‐targeted therapy , 2022, Histopathology.

[9]  M. Weichenthal,et al.  TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. , 2021, European journal of cancer.

[10]  C. Antonescu,et al.  Gastrointestinal stromal tumors with BRAF gene fusions. A report of two cases showing low or absent KIT expression resulting in diagnostic pitfalls , 2021, Genes, chromosomes & cancer.

[11]  S. Chew,et al.  SKAP2-BRAF fusion and response to an MEK inhibitor in a patient with metastatic melanoma resistant to immunotherapy , 2021, BMJ Case Reports.

[12]  H. Ueno,et al.  Establishment and implementation of Cancer Genomic Medicine in Japan , 2020, Cancer science.

[13]  Douglas B. Johnson,et al.  MEK inhibitors in non-V600 BRAF mutations and fusions , 2020, Oncotarget.

[14]  M. Xing,et al.  TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel , 2020, Proceedings of the National Academy of Sciences.

[15]  E. Nagore,et al.  Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients * , 2020, The British journal of dermatology.

[16]  N. Nazmun,et al.  BRAF mutation and its inhibitors in sarcoma treatment , 2020, Cancer medicine.

[17]  J. Chung.  BRAF and TERT promoter mutations: clinical application in thyroid cancer. , 2020, Endocrine journal.

[18]  R. Gray,et al.  Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131) , 2020, Clinical Cancer Research.

[19]  N. Rosen,et al.  Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer , 2019, Clinical Cancer Research.

[20]  A. Bossler,et al.  Urothelial carcinoma with an NRF1-BRAF rearrangement and response to targeted therapy , 2019, Cold Spring Harbor molecular case studies.

[21]  Akihiko Yoshida,et al.  Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study , 2019, Cancer science.

[22]  R. Yaeger,et al.  Targeting Alterations in the RAF-MEK Pathway. , 2019, Cancer discovery.

[23]  Hideo Nakamura,et al.  BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity , 2018, Brain pathology.

[24]  P. Gendron,et al.  Novel PDE10A-BRAF Fusion With Concomitant NF1 Mutation Identified in an Undifferentiated Sarcoma of Infancy With Sustained Response to Trametinib. , 2018, JCO precision oncology.

[25]  A. Protopopov,et al.  Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas , 2018, Clinical Cancer Research.

[26]  S. Ganesan,et al.  BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. , 2018, JCO precision oncology.

[27]  P. Poulikakos,et al.  New perspectives for targeting RAF kinase in human cancer , 2017, Nature Reviews Cancer.

[28]  C. Antonescu,et al.  Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma , 2017, The American journal of surgical pathology.

[29]  Catherine A. Shang,et al.  Whole-genome landscapes of major melanoma subtypes , 2017, Nature.

[30]  V. Miller,et al.  Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein , 2014, Journal of Hematology & Oncology.

[31]  Junfeng Xia,et al.  BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. , 2012, Cancer discovery.

[32]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[33]  C. Antonescu,et al.  Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors , 2017, The American journal of surgical pathology.

[34]  T. Higashi,et al.  Statistics of soft-tissue sarcoma in Japan: Report from the Bone and Soft Tissue Tumor Registry in Japan. , 2017, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.